Why october is a smart time to get fall respiratory vaccines

For many adults, the fall vaccine conversation is not really about one shot. It is about timing several respiratory-virus protections so they can work before flu, COVID-19 and RSV begin circulating more widely. Public health guidance and recent reporting both point to October as a practical month to act, especially for adults 45 and older who are more likely to have chronic conditions or age-related risk factors that can make respiratory infections harder to recover from. ([apnews.com](https://apnews.com/article/550fb1f77d84342f53fb0f7d28618c38))

The basic message is straightforward: vaccination does not guarantee you will not get sick, but it can lower the odds of severe illness, hospitalization and missed time from work, travel or family plans. For older adults, that protection matters most when it is in place before virus activity rises. ([apnews.com](https://apnews.com/article/550fb1f77d84342f53fb0f7d28618c38))

What happened

The Associated Press reported that infectious-disease and emergency-care experts are encouraging people to get flu shots in October, when vaccination can better line up with the season ahead. The reporting also noted that updated COVID-19 vaccines are available and that RSV vaccination may be appropriate for people at higher risk, particularly older adults and those with certain medical conditions. ([apnews.com](https://apnews.com/article/550fb1f77d84342f53fb0f7d28618c38))

That advice fits with current CDC guidance. The agency says flu vaccination should be offered ideally during September or October, while vaccination can continue later in the season as long as flu viruses are circulating. CDC also says the best time for RSV vaccination in adults is late summer and early fall, and that a 2026-2027 COVID-19 vaccine is recommended for adults 18 and older. ([cdc.gov](https://www.cdc.gov/flu/prevention/?utm_source=openai))

Why it matters after 45

Adults in their mid-40s and older are not the only people who need seasonal vaccines, but this age group is more likely to be managing blood pressure problems, diabetes, lung disease, heart disease or immune-suppressing treatments. Those conditions can raise the stakes if flu, COVID-19 or RSV turns into pneumonia or another severe complication. CDC says flu can be especially dangerous for people 65 and older and for people of any age with chronic health problems. CDC likewise notes that RSV can be severe in older adults and in people with chronic heart or lung disease or weakened immune systems. ([apnews.com](https://apnews.com/article/550fb1f77d84342f53fb0f7d28618c38))

Age also matters because immune responses can weaken over time. That is one reason the CDC preferentially recommends higher-dose, adjuvanted or recombinant flu vaccines for adults 65 and older, while stressing that people should not delay vaccination if the preferred product is not available. ([cdc.gov](https://cdc.gov/flu/highrisk/65over.htm?utm_source=openai))

What the evidence actually shows

The evidence base for seasonal vaccination is strongest on prevention of severe outcomes, not on perfect prevention of every infection. CDC says flu vaccination remains recommended every season for everyone 6 months and older, and that age-appropriate products should be used. For adults 65 and older, higher-dose, adjuvanted and recombinant flu vaccines are preferred because studies support greater potential benefit in that group. ([cdc.gov](https://www.cdc.gov/flu/vaccines/?utm_source=openai))

There is also a new option for adults 50 and older: FDA approved MFLUSIVA, an mRNA flu vaccine, in 2026. FDA says it is indicated for adults 50 and older, with the indication for people 65 and older approved under accelerated approval. AP reported that one study found the vaccine was more effective than a standard shot against symptomatic illness in adults 50 to 64. Because that figure came from a single study summarized in news coverage, it should be treated as promising but not the final word on comparative performance across all seasons and populations. ([fda.gov](https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva?trk=public_post_comment-text&utm_source=openai))

For RSV, CDC recommends a single dose for all adults 75 and older and for adults 50 to 74 who are at increased risk for severe RSV illness. CDC also says RSV vaccination is not annual, and that one dose provides protection for at least two years in adults 50 and older. ([cdc.gov](https://cdc.gov/rsv/vaccines/adults.html?utm_source=openai))

COVID-19 vaccine guidance has also changed from the broad universal language many people remember from earlier in the pandemic. CDC now says the 2026-2027 COVID-19 vaccine is recommended for adults 18 and older, and adults 65 and older are specifically included in the group for whom vaccination is recommended. AP noted that updated COVID shots are available now and that older adults remain among those most likely to benefit from reduced severe disease. ([cdc.gov](https://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html?trk=public_post_comment-text&utm_source=openai))

What remains uncertain

Not every expert group speaks with exactly the same emphasis on timing or product choice, and recommendations can change as new formulations and safety data emerge. For example, CDC’s current RSV advice is more selective than some earlier public messaging, focusing on age and risk factors rather than recommending vaccination for every adult over 50. That means the most useful question is not simply whether a vaccine exists, but whether it fits a person’s age, risk profile and prior vaccination history. ([cdc.gov](https://cdc.gov/rsv/vaccines/adults.html?utm_source=openai))

There is also uncertainty in any fall-season forecast. Flu, COVID-19 and RSV do not always peak at the same time, and local spread can vary by region. That is one reason CDC continues to emphasize getting vaccinated before respiratory viruses become widespread, rather than waiting for a perfect calendar date. ([cdc.gov](https://www.cdc.gov/flu/prevention/?utm_source=openai))

What adults 45 and older may want to discuss with a clinician

If you are 45 or older, fall is a good time to review whether you are up to date on flu, COVID-19 and RSV vaccines, especially if you live with diabetes, heart disease, chronic lung disease, obesity, kidney disease or another condition that raises the risk of severe infection. Adults 50 and older should also ask whether their flu option is age-appropriate, and adults 65 and older may want to ask specifically about high-dose, adjuvanted or recombinant flu vaccines. ([cdc.gov](https://cdc.gov/vaccines/by-age/?utm_source=openai))

It is also worth asking about timing if you have an upcoming trip, family gathering or medical procedure. CDC says it takes about two weeks after flu vaccination for antibodies to develop, so getting ahead of exposure is the point. AP reported the same general theme: a well-timed shot is less about perfecting the calendar and more about getting protection in place before virus season accelerates. ([cdc.gov](https://www.cdc.gov/flu/travelersfacts/index.html?utm_source=openai))

Anyone who develops trouble breathing, chest pain, confusion, bluish lips, severe dehydration or symptoms that worsen quickly should seek urgent medical care. Those can be signs of a serious respiratory infection, and they should not be managed as routine seasonal illness. ([cdc.gov](https://www.cdc.gov/flu/prevention/?utm_source=openai))

For many adults, the practical takeaway is simple: October is not too early to think about fall respiratory protection, and for some people it may be the best month to get it done. ([apnews.com](https://apnews.com/article/550fb1f77d84342f53fb0f7d28618c38))